[177Lu]Lu-PSMA-597 / Telix - LARVOL DELTA

Dose optimisation and PSMA receptor intensification with 177Lu-PSMA-597 in metastatic castration-resistant prostate cancer (mCRPC): The randomised phase II OPTIMAL-PSMA trial. (ASCO-GU 2026) - P2 | "A phase 1 dose escalation study previously found 22Gbq dose of 177LuPSMA-617 over 15 days to be safe and tolerable, but randomised data compared to conventional dosing are lacking. 177Lu-SPECT and PSMA PET quantitation will be used to assess both treatment response and compare biologic effective dose delivered with a dose intensified versus SoC 177LuPSMA administration. Clinical trial information: ACTRN12625000971437."

Clinical • Metastases • P2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor